The NPNT portfolio presents Empalife as a research direction for personal navigation across health and life goals. The public version is labelled a closed demonstration prototype and technical pilot v0.6 dated 20 August 2026. It describes six functional tasks: concentration, physical fitness, sleep, stress, long-term health and a combined route. The method starts with one leading goal and limits the result to three actions with sources, constraints and a success check. The confirmed stage is demonstration of a product model using synthetic data. Only synthetic or fully de-identified test files are permitted in the technical pilot; real patient information must not be uploaded. The practical purpose is to reduce recommendation overload and show when a low-risk action may be enough and when professional review is needed. The service does not diagnose, prescribe treatment, change doses or promise a longer life. Medical decisions remain with a clinician. User benefit, module safety and suitability for real data remain hypotheses requiring separate validation and authorisation.
Project review
Empalife: reducing a health plan to three testable priorities
The NPNT portfolio presents Empalife as a research direction for personal navigation across health and life goals. The public version is labelled a closed demonstration prototype and technical pilot v0.6 dated 20 August 2026. It describes six functional tasks: concentration, physical fitness, sleep, stress, long-term health and a combined route. The method starts with one leading goal and limits the result to three actions with sources, constraints and a success check. The confirmed stage is demonstration of a product model using synthetic data. Only synthetic or fully de-identified test files are permitted in the technical pilot; real patient information must not be uploaded. The practical purpose is to reduce recommendation overload and show when a low-risk action may be enough and when professional review is needed. The service does not diagnose, prescribe treatment, change doses or promise a longer life. Medical decisions remain with a clinician. User benefit, module safety and suitability for real data remain hypotheses requiring separate validation and authorisation.